South Africa at a glance
- Population
- 64.7 million 2025
- Life expectancy at birth
- 66.3 years, 2024
- People aged 65 and over
- 6.9 % of people, 2025
- Health spending per person
- 537 US$ per person, 2023
- Doctors
- 0.79 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
South Africa Biosimilar Development Services Market Industry Trends and Forecast to 2034: Segmented by (Service, Molecule, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$38.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $16.9 Mn | — | — |
| 2025 (base) | $19.1 Mn | +$2.2 Mn | — |
| 2026 (forecast) | $21.6 Mn | +$2.5 Mn | +13.1% |
| 2027 (forecast) | $24.4 Mn | +$2.8 Mn | +27.9% |
| 2028 (forecast) | $27.6 Mn | +$3.2 Mn | +44.7% |
| 2029 (forecast) | $31.2 Mn | +$3.6 Mn | +63.6% |
| 2030 (forecast) | $35.3 Mn | +$4.1 Mn | +85.1% |
| 2031 (forecast) | $39.9 Mn | +$4.6 Mn | +109.3% |
| 2032 (forecast) | $45.1 Mn | +$5.2 Mn | +136.7% |
| 2033 (forecast) | $51.0 Mn | +$5.9 Mn | +167.7% |
| 2034 (forecast) | $57.7 Mn | +$6.7 Mn | +202.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $19.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $57.7 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 13.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Service, molecule and end user (see all) |
| Key players | Samsung Biologics, Celltrion, WuXi Biologics, Intas Pharmaceuticals, Syngene International (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Biosimilar development services help companies develop, test and gain approval for biosimilar medicines.
Key segments of the biosimilar Development Services market include service (Analytical Characterization, Clinical Studies and Manufacturing) and molecule (Antibodies, Insulins and Others).
Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the biosimilar Development Services market. Many companies now outsource work they used to do in-house.
Advanced therapies, AI-driven operations and expansion in India, China and Southeast Asia give the biosimilar Development Services market room to grow.
Capacity shortages, strict quality rules, data security concerns and pricing pressure hold back the biosimilar Development Services market.
The biosimilar Development Services market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone.[1]
[1] National Department of Health. Checked 14 Nov 2026.
Licensing, quality standards and payment models from public and private payers shape how biosimilar Development Services services are delivered and paid for in South Africa. Government health programs and insurance coverage are key to access.
What doctors and scientists are doing in Biosimilar Development Services right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.
From our blog
South Africa · 1 shared keyword
South Africa
South Africa
South Africa
South Africa
South Africa
Pharmaceuticals · South Africa
Pharmaceuticals · South Africa
Pharmaceuticals · South Africa
Medical Devices · South Africa
Pharmaceuticals · South Africa
Pharmaceuticals · South Africa